Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2024Cancer MedicineOpen Access

A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYanqiu XiongChengdu Medical CollegeSLShanshan LiangGuiyang College of Traditional Chinese MedicineWTWenjiao TangSichuan University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Xiong et al. (2024) studied this question.

synapsesocial.com/papers/68e59c66b6db64358753758fhttps://doi.org/10.1002/cam4.70193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma2017 · 36 citations
  2. 2A simple additive staging system for newly diagnosed multiple myeloma2022 · 101 citations
  3. 3How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership2023 · 1 citations
  4. 4Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value2013 · 117 citations
  5. 5Proposed risk‐scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma2022 · 19 citations